BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Marginean CM, Cioboata R, Olteanu M, Vasile CM, Popescu M, Popescu AIS, Bondari S, Pirscoveanu D, Marginean IC, Iacob GA, Popescu MD, Stanciu M, Mitrut P. The Importance of Accurate Early Diagnosis and Eradication in Helicobacter pylori Infection: Pictorial Summary Review in Children and Adults. Antibiotics (Basel) 2022;12. [PMID: 36671261 DOI: 10.3390/antibiotics12010060] [Reference Citation Analysis]
2 Wang YZ, Chen J, Pei SQ, Wang C, Han G, Kan LD, Li LC. Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection. Drug Dev Res 2022. [PMID: 36567647 DOI: 10.1002/ddr.22025] [Reference Citation Analysis]
3 Moadelighomi SZJ, Mirpour M, Ghasemi MF. Eugenol contributes to decreased expression of rpoD and genes in clinically isolated Helicobacter pylori: An in vitro study using real-time-PCR technique. Gene Reports 2022;29:101664. [DOI: 10.1016/j.genrep.2022.101664] [Reference Citation Analysis]
4 Hu Y, Zhu Y, Lu NH. The management of Helicobacter pylori infection and prevention and control of gastric cancer in China. Front Cell Infect Microbiol 2022;12:1049279. [PMID: 36530421 DOI: 10.3389/fcimb.2022.1049279] [Reference Citation Analysis]
5 Fekadu S, Engiso H, Seyfe S, Iizasa H, Godebo A, Deyno S, Yoshiyama H. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: A systematic review and meta-analysis.. [DOI: 10.21203/rs.3.rs-2078777/v1] [Reference Citation Analysis]
6 Shi X, Wang C, Meng F, Ma S, Xu G, Liu T, Guo X, Li H, Qi X. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgrad Med 2022. [PMID: 35860966 DOI: 10.1080/00325481.2022.2105094] [Reference Citation Analysis]
7 Pop R, Tăbăran A, Ungur AP, Negoescu A, Cătoi C. Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles. Pharmaceutics 2022;14:1463. [DOI: 10.3390/pharmaceutics14071463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Ortiz-ramírez P, Hernández-ochoa B, Ortega-cuellar D, González-valdez A, Martínez-rosas V, Morales-luna L, Arreguin-espinosa R, Castillo-rodríguez RA, Canseco-ávila LM, Cárdenas-rodríguez N, Pérez de la Cruz V, Montiel-gonzález AM, Gómez-chávez F, Gómez-manzo S. Biochemical and Kinetic Characterization of the Glucose-6-Phosphate Dehydrogenase from Helicobacter pylori Strain 29CaP. Microorganisms 2022;10:1359. [DOI: 10.3390/microorganisms10071359] [Reference Citation Analysis]
9 Miri AH, Kamankesh M, Llopis-lorente A, Liu C, Wacker MG, Haririan I, Asadzadeh Aghdaei H, Hamblin MR, Yadegar A, Rad-malekshahi M, Zali MR. The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications. Front Pharmacol 2022;13:917184. [DOI: 10.3389/fphar.2022.917184] [Reference Citation Analysis]
10 Dai YY, Qin C, Huang GR, Qin YC, Huang YY, Huang YQ, Zhao LJ. Linolenic Acid-Metronidazole: a Compound Relieving Drug Resistance and Inhibiting Helicobacter pylori. Antimicrob Agents Chemother 2022;:e0007322. [PMID: 35758720 DOI: 10.1128/aac.00073-22] [Reference Citation Analysis]
11 Meliț LE, Mărginean CO, Săsăran MO. The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics. Children 2022;9:795. [DOI: 10.3390/children9060795] [Reference Citation Analysis]
12 Antoniciello F, Roncarati D, Zannoni A, Chiti E, Scarlato V, Chiappori F. Targeting the Essential Transcription Factor HP1043 of Helicobacter pylori: A Drug Repositioning Study. Front Mol Biosci 2022;9:887564. [DOI: 10.3389/fmolb.2022.887564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Šudomová M, Hassan STS. Gossypol from Gossypium spp. Inhibits Helicobacter pylori Clinical Strains and Urease Enzyme Activity: Bioactivity and Safety Assessments. Sci Pharm 2022;90:29. [DOI: 10.3390/scipharm90020029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tavares MC, Olímpio CRSDG, de Fátima Â, Modolo LV, de Oliveira JAC, da Silva-filho CJA, Barbosa FG, Mafezoli J, Santos JCC. Interaction and inhibition mechanism of urease in vitro and soil system by a natural benzylisothiocyanate isolated from Moringa oleifera. Industrial Crops and Products 2022;178:114580. [DOI: 10.1016/j.indcrop.2022.114580] [Reference Citation Analysis]
15 Huang Y, Li R, Dai Y, Qin C, He J, Yang S, Wang T, Su Y, Jia L, Zhao W. Rhamnolipid-assisted black phosphorus nanosheets with efficient isolinderalactone loading against drug resistant Helicobacter pylori. Materials & Design 2022;216:110536. [DOI: 10.1016/j.matdes.2022.110536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Klang E, Soffer S, Barash Y, Shachar E, Lahat A. Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications. CEG 2022;Volume 15:51-8. [DOI: 10.2147/ceg.s342048] [Reference Citation Analysis]
17 Yan J, Peng C, Chen P, Zhang W, Jiang C, Sang S, Zhu W, Yuan Y, Hong Y, Yao M. In-vitro anti-Helicobacter pylori activity and preliminary mechanism of action of Canarium album Raeusch. fruit extracts. J Ethnopharmacol 2022;283:114578. [PMID: 34464702 DOI: 10.1016/j.jep.2021.114578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Noorbakhsh N, Nikpour S, Salehi M. The efficacy and safety of furazolidone-bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotic supplementation. Gastroenterol Hepatol Bed Bench 2022;15:146-52. [PMID: 35845306] [Reference Citation Analysis]
19 Bai X, Zhu M, He Y, Wang T, Tian D, Shu J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Arch Microbiol 2022;204:692. [PMID: 36344628 DOI: 10.1007/s00203-022-03314-w] [Reference Citation Analysis]
20 Pitchon V, Aubert E, Vonthron C, Fechter P. How history can help present research of new antimicrobial strategies: the case of cutaneous infections’ remedies containing metals from the Middle Age Arabic pharmacopeia. Medicinal Plants as Anti-Infectives 2022. [DOI: 10.1016/b978-0-323-90999-0.00016-1] [Reference Citation Analysis]
21 Lacerda DC, Trindade da Costa PC, Paulino do Nascimento LC, de Brito Alves JL. Probiotics for gastrointestinal health and disease treatment. Probiotics for Human Nutrition in Health and Disease 2022. [DOI: 10.1016/b978-0-323-89908-6.00022-4] [Reference Citation Analysis]
22 Zhang Y, Meng F, Jin J, Wang J, Gu BB, Peng JB, Ye LP. Ninety-four thousand-case retrospective study on antibacterial drug resistance of Helicobacter pyloriWorld J Clin Cases 2021; 9(35): 10838-10849 [DOI: 10.12998/wjcc.v9.i35.10838] [Reference Citation Analysis]
23 Penumetcha SS, Ahluwalia S, Irfan R, Khan SA, Rohit Reddy S, Vasquez Lopez ME, Zahid M, Busmail A, Mohammed L. The Efficacy of Probiotics in the Management of Helicobacter Pylori: A Systematic Review. Cureus 2021;13:e20483. [PMID: 35047301 DOI: 10.7759/cureus.20483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kasza K, Gurnani P, Hardie KR, Cámara M, Alexander C. Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account. Adv Drug Deliv Rev 2021;178:113973. [PMID: 34530014 DOI: 10.1016/j.addr.2021.113973] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
25 Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Haseena, Khan A, Aslam F, Kanwal T, Shah MR, Khalil AAK, Shah SWA, Alshammari EM, El-Masry EA, Batiha GE, Baty RS. Enhanced Antibacterial Potential of Amoxicillin against Helicobacter pylori Mediated by Lactobionic Acid Coated Zn-MOFs. Antibiotics (Basel) 2021;10:1071. [PMID: 34572653 DOI: 10.3390/antibiotics10091071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613-29. [PMID: 34002081 DOI: 10.1038/s41575-021-00449-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 32.0] [Reference Citation Analysis]
28 Aloutaibi GT, Al-malki AL, Balgoon MJ, Bahaidarah SA, Moselhy SS. Rheumatic Heart Disease and Its Association with H. pylori Infection. J Pure Appl Microbiol 2021;15:580-586. [DOI: 10.22207/jpam.15.2.42] [Reference Citation Analysis]
29 De Francesco V, Zullo A, Gatta L, Manta R, Pavoni M, Saracino IM, Fiorini G, Vaira D. Rescue Therapies for H. pylori Infection in Italy. Antibiotics (Basel) 2021;10:525. [PMID: 34063624 DOI: 10.3390/antibiotics10050525] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Zhang C, Cao M, Lv T, Wang H, Liu X, Xie Y, Lv N, Chen H, Cram DS, Zhong J, Zhou L. Molecular testing for H. pylori clarithromycin and quinolone resistance: a prospective Chinese study. Eur J Clin Microbiol Infect Dis 2021;40:1599-608. [PMID: 33646449 DOI: 10.1007/s10096-021-04188-4] [Reference Citation Analysis]
31 Zhong X, Chen O, Zhou T, Lü M, Wan J. Cytotoxin-Associated Gene A-Positive Helicobacter pylori Promotes Autophagy in Colon Cancer Cells by Inhibiting miR-125b-5p. Can J Infect Dis Med Microbiol 2021;2021:6622092. [PMID: 33791049 DOI: 10.1155/2021/6622092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Diallo S, Bassène ML, Fall MP, Issa A, Thioubou MA. Evaluation of Three Helicobacter pylori Eradication Protocols in a Digestive Endoscopy Center in Dakar. OJGas 2021;11:244-254. [DOI: 10.4236/ojgas.2021.1111025] [Reference Citation Analysis]
33 Raina H, Sainani R, Parray A, Wani AH, Asharaf U, Raina MA. Efficacy of levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) regimen compared with standard triple therapy to eradicate Helicobacter pylori infection: a prospective randomized study from a tertiary hospital in India. Gastroenterol Hepatol Bed Bench 2021;14:342-8. [PMID: 34659662] [Reference Citation Analysis]
34 张 孟. Clinical Study of Hp Infection and Gastric Lesions in Adults of Different Ages in Qinghai. ACM 2021;11:4298-4309. [DOI: 10.12677/acm.2021.119629] [Reference Citation Analysis]
35 Dey TK, Karmakar BC, Sarkar A, Paul S, Mukhopadhyay AK. A Mouse Model of Helicobacter pylori Infection. Methods Mol Biol 2021;2283:131-51. [PMID: 33765316 DOI: 10.1007/978-1-0716-1302-3_14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
36 Sánchez-Trigueros MI, Méndez-Cruz F, Pineda-Peña EA, Rivera-Espinoza Y, Castañeda-Hernández G, Chávez-Piña AE. Synergistic protective effects between docosahexaenoic acid and omeprazole on the gastrointestinal tract in the indomethacin-induced injury model. Drug Dev Res 2021;82:543-52. [PMID: 33319390 DOI: 10.1002/ddr.21772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Sun X, Zhang S, Ren J, Udenigwe CC. Sialic acid-based strategies for the prevention and treatment of Helicobacter pylori infection: Emerging trends in food industry. Critical Reviews in Food Science and Nutrition. [DOI: 10.1080/10408398.2020.1846157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Kalkanlı Taş S, Kırkık D, Öztürk K, Tanoğlu A. Determination of B- and T- cell epitopes for Helicobacter pylori cagPAI: An in silico approach. Turk J Gastroenterol 2020;31:713-20. [PMID: 33169709 DOI: 10.5152/tjg.2020.19154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Al-khafaji ZM, Mahmood AB, Mahmood MB. Food constituents for inhibition of BabA of Helicobacter pylori. J Drug Delivery Ther 2020;10:152-163. [DOI: 10.22270/jddt.v10i5-s.4358] [Reference Citation Analysis]
40 Biernat MM, Bińkowska A, Łaczmański Ł, Biernat P, Krzyżek P, Gościniak G. Phenotypic and Genotypic Analysis of Resistant Helicobacter pylori Strains Isolated from Children with Gastrointestinal Diseases. Diagnostics (Basel) 2020;10:E759. [PMID: 32992661 DOI: 10.3390/diagnostics10100759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Vieira RR, Fontes LES, Pacheco RL, Fernandes MA, Malta PP, Riera R. Proton pump inhibitor- and clarithromycin-based triple therapies for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2020;2021. [DOI: 10.1002/14651858.cd013734] [Reference Citation Analysis]
42 Sun X, Zhang S, Udenigwe CC, Ren J, Li S, Wang H, Liu X. Wheat Germ-Derived Peptides Exert Antiadhesive Activity against Helicobacter pylori : Insights into Structural Characteristics of Identified Peptides. J Agric Food Chem 2020;68:11954-74. [DOI: 10.1021/acs.jafc.0c04367] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
43 Park CG, Kim S, Jeon HS, Han S. Validation of loop-mediated isothermal amplification to detect Helicobacter pylori and 23S rRNA mutations: A prospective, observational clinical cohort study. J Clin Lab Anal 2021;35:e23563. [PMID: 32893424 DOI: 10.1002/jcla.23563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Song MY, Lee DY, Kim EH. Anti-inflammatory and anti-oxidative effect of Korean propolis on Helicobacter pylori-induced gastric damage in vitro. J Microbiol 2020;58:878-85. [PMID: 32876916 DOI: 10.1007/s12275-020-0277-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
45 Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
46 Kikuchi S, Imai H, Tani Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2020;8:CD013113. [PMID: 32844430 DOI: 10.1002/14651858.CD013113.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
47 Grande R, Sisto F, Puca V, Carradori S, Ronci M, Aceto A, Muraro R, Mincione G, Scotti L. Antimicrobial and Antibiofilm Activities of New Synthesized Silver Ultra-NanoClusters (SUNCs) Against Helicobacter pylori. Front Microbiol 2020;11:1705. [PMID: 32849359 DOI: 10.3389/fmicb.2020.01705] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
48 Soluri MF, Puccio S, Caredda G, Edomi P, D'Elios MM, Cianchi F, Troilo A, Santoro C, Sblattero D, Peano C. Defining the Helicobacter pylori Disease-Specific Antigenic Repertoire. Front Microbiol 2020;11:1551. [PMID: 32849324 DOI: 10.3389/fmicb.2020.01551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Zhang J, Chen Z, Kong J, Liang Y, Chen K, Chang Y, Yuan H, Wang Y, Liang H, Li J, Mao M, Li J, Xing G. Fullerenol Nanoparticles Eradicate Helicobacter pylori via pH-Responsive Peroxidase Activity. ACS Appl Mater Interfaces 2020. [PMID: 32486636 DOI: 10.1021/acsami.0c05509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Darmani H, Smadi EAM, Bataineh SMB. Blue light emitting diodes enhance the antivirulence effects of Curcumin against Helicobacter pylori. J Med Microbiol 2020;69:617-24. [PMID: 32100708 DOI: 10.1099/jmm.0.001168] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
51 Di J, Zhang J, Cao L, Huang TT, Zhang JX, Mi YN, Xiao X, Yan PP, Wu ML, Yao T, Liu DZ, Liu J, Cao YX. Hydrogen Peroxide-Mediated Oxygen Enrichment Eradicates Helicobacter pylori In Vitro and In Vivo. Antimicrob Agents Chemother 2020;64:e02192-19. [PMID: 32071054 DOI: 10.1128/AAC.02192-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Salillas S, Sancho J. Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens. Int J Mol Sci 2020;21:E1881. [PMID: 32164177 DOI: 10.3390/ijms21051881] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
53 Satuluri SH, Katari SK, Pasala C, Amineni U. Novel and potent inhibitors for dihydropteroate synthase of Helicobacter pylori. J Recept Signal Transduct Res 2020;40:246-56. [PMID: 32098568 DOI: 10.1080/10799893.2020.1731533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.Int J Mol Sci. 2020;21. [PMID: 32046317 DOI: 10.3390/ijms21031136] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
55 Ofori EG, Adinortey CA, Bockarie AS, Kyei F, Tagoe EA, Adinortey MB. Helicobacter pylori Infection, Virulence Genes' Distribution and Accompanying Clinical Outcomes: The West Africa Situation. Biomed Res Int 2019;2019:7312908. [PMID: 31886245 DOI: 10.1155/2019/7312908] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
56 de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019; 25(37): 5578-5589 [PMID: 31602159 DOI: 10.3748/wjg.v25.i37.5578] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 86] [Article Influence: 20.5] [Reference Citation Analysis]
57 Choi YK, Ahn JY, Won SH, Jung K, Na HK, Jung KW, Kim DH, Lee JH, Choi KD, Song HJ, Lee GH, Jung HY. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study. J Gastroenterol Hepatol 2019;34:1696-702. [PMID: 30811663 DOI: 10.1111/jgh.14639] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
58 Livzan MA. [Underwater rocks of anti - helicobacter therapy]. Ter Arkh 2019;91:141-7. [PMID: 32598766 DOI: 10.26442/00403660.2019.08.000386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comparative Immunology, Microbiology and Infectious Diseases 2019;64:99-108. [DOI: 10.1016/j.cimid.2019.02.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
60 Shetty V, Lamichhane B, Tay CY, Pai GC, Lingadakai R, Balaraju G, Shetty S, Ballal M, Chua EG. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients. Gut Pathog. 2019;11:21. [PMID: 31110563 DOI: 10.1186/s13099-019-0305-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
61 Aiba Y, Umeda K, Rahman S, Nguyen SV, Komatsu Y. Synergistic effect of anti-Helicobacter pylori urease immunoglobulin Y from egg yolk of immunized hens and Lactobacillus johnsonii No.1088 to inhibit the growth of Helicobacter pylori in vitro and in vivo. Vaccine 2019;37:3106-12. [PMID: 31031029 DOI: 10.1016/j.vaccine.2019.04.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
62 Celik MM, Duran N. An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid. Revista Romana de Medicina de Laborator 2019;27:63-71. [DOI: 10.2478/rrlm-2019-0003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
63 Zanotti G, Cendron L. Structural Aspects of Helicobacter pylori Antibiotic Resistance. Adv Exp Med Biol 2019;1149:227-41. [PMID: 31016632 DOI: 10.1007/5584_2019_368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
64 Gaiani F, De'Angelis N, Kayali S, Manfredi M, Di Mario F, Leandro G, Ghiselli A, Fornaroli F, De'Angelis GL. Clinical approach to the patient with acute gastrointestinal bleeding. Acta Biomed 2018;89:12-9. [PMID: 30561412 DOI: 10.23750/abm.v89i8-S.7861] [Reference Citation Analysis]
65 Yang-Ou YB, Hu Y, Zhu Y, Lu NH. The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis. Helicobacter 2018;23:e12535. [PMID: 30191635 DOI: 10.1111/hel.12535] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
66 Akdeniz V, Akalın AS, Özer E. ROLE OF PROBIOTICS IN Helicobacter pylori INFECTION. GIDA / THE JOURNAL OF FOOD 2018. [DOI: 10.15237/gida.gd18062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
67 Juan C, Torrens G, Barceló IM, Oliver A. Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens. Microbiol Mol Biol Rev 2018;82:e00033-18. [PMID: 30209071 DOI: 10.1128/MMBR.00033-18] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
68 Kikuchi S, Naoki Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2018. [DOI: 10.1002/14651858.cd013113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Farzi N, Behzad C, Hasani Z, Alebouyeh M, Zojaji H, Zali MR. Characterization of clarithromycin heteroresistance among Helicobacter pylori strains isolated from the antrum and corpus of the stomach. Folia Microbiol (Praha) 2019;64:143-51. [PMID: 30097895 DOI: 10.1007/s12223-018-0637-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
70 Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol 2018;12:819-27. [PMID: 29976092 DOI: 10.1080/17474124.2018.1496017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
71 Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob 2018;17:29. [PMID: 29950163 DOI: 10.1186/s12941-018-0281-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
72 Liu Q, Meng X, Li Y, Zhao CN, Tang GY, Li S, Gan RY, Li HB. Natural Products for the Prevention and Management of Helicobacter pylori Infection. Compr Rev Food Sci Food Saf 2018;17:937-52. [PMID: 33350111 DOI: 10.1111/1541-4337.12355] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
73 Angsantikul P, Thamphiwatana S, Zhang Q, Spiekermann K, Zhuang J, Fang RH, Gao W, Obonyo M, Zhang L. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection. Adv Ther (Weinh) 2018;1:1800016. [PMID: 30320205 DOI: 10.1002/adtp.201800016] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 13.4] [Reference Citation Analysis]
74 Peng X, Zhang R, Duan G, Wang C, Sun N, Zhang L, Chen S, Fan Q, Xi Y. Production and delivery of Helicobacter pylori NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity. Sci Rep 2018;8:6435. [PMID: 29691472 DOI: 10.1038/s41598-018-24879-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
75 Хіміон ЛВ, Ященко ОБ, Данилюк СВ, Ситюк ТО. Modern approaches to the diagnosis and management of gastric and duodenal ulcer at the primary level of medical care. СМ 2018;0:6-12. [DOI: 10.30841/2307-5112.1.2018.132593] [Reference Citation Analysis]
76 Rosenheim JA. Short- and long-term evolution in our arms race with cancer: Why the war on cancer is winnable. Evol Appl 2018;11:845-52. [PMID: 29928294 DOI: 10.1111/eva.12612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Doulberis M, Kotronis G, Thomann R, Polyzos SA, Boziki M, Gialamprinou D, Deretzi G, Katsinelos P, Kountouras J. Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far? Helicobacter 2018;23. [PMID: 29181894 DOI: 10.1111/hel.12454] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 12.8] [Reference Citation Analysis]